[1]于守杰,贾 倩.艾拉莫德联合依那西普治疗难治性类风湿关节炎的疗效[J].医学信息,2020,33(09):140-141.[doi:10.3969/j.issn.1006-1959.2020.09.045]
　YU Shou-jie,JIA Qian.Effect of Iguratimod with Etanercept in the Treatment of Refractory Rheumatoid Arthritis[J].Medical Information,2020,33(09):140-141.[doi:10.3969/j.issn.1006-1959.2020.09.045]
点击复制

艾拉莫德联合依那西普治疗难治性类风湿关节炎的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年09期
页码:
140-141
栏目:
药物与临床
出版日期:
2020-05-01

文章信息/Info

Title:
Effect of Iguratimod with Etanercept in the Treatment of Refractory Rheumatoid Arthritis
文章编号:
1006-1959（2020）09-0140-02
作者:
于守杰; 贾 倩
（临沂市人民医院风湿免疫科，山东 临沂 276000）
Author(s):
YU Shou-jie; JIA Qian
(Department of Rheumatology and Immunology,Linyi People Hospital,Linyi 276000,Shandong,China)
关键词:
难治性类风湿关节炎; 艾拉莫德; 依那西普; 炎症因子; 免疫功能
Keywords:
Refractory rheumatoid arthritis; Iguratimod; Etanercept; Inflammatory factors; Immune function
分类号:
R593.22
DOI:
10.3969/j.issn.1006-1959.2020.09.045
文献标志码:
A
摘要:
目的 探究艾拉莫德联合依那西普治疗难治性类风湿关节炎的疗效。方法 选取2017年8月~2019年11月我院诊治的78例难治性类风湿关节炎患者，按随机数字表法分为对照组和观察组，各39例。对照组给予依那西普治疗，观察组给予在对照组基础上联合艾拉莫德治疗，比较两组临床疗效、类风湿因子（RF）、肿瘤坏死因子（TNF-α）、血管内皮生长因子（VEGF）水平和血清免疫球蛋白[免疫球蛋白A（IgA）、免疫球蛋白M（IgM）、免疫球蛋白G（IgG）]。结果 观察组治疗总有效率为94.87%，高于对照组的76.92%，差异有统计学意义（P＜0.05）；治疗后，观察组RF、TNF-α、VEGF、IgA、IgM、IgG低于对照组，差异有统计学意义（P＜0.05）。结论 艾拉莫德联合依那西普治疗可有效降低难治性类风湿关节炎患者炎症因子水平，改善免疫球蛋白，提高治疗效果。
Abstract:
Objective To investigate the efficacy of Iguratimod combined with etanercept in the treatment of refractory rheumatoid arthritis.Methods 78 patients with refractory rheumatoid arthritis diagnosed and treated in our hospital from August 2017 to November 2019 were selected and divided into a control group and an observation group with a random number table method, 39 cases each. The control group was treated with etanercept, and the observation group was given combined with Iguratimod treatment based on the control group. The clinical efficacy, rheumatoid factor (RF), tumor necrosis factor (TNF-α), and vascular endothelial growth factor were compared (VEGF) level and serum immunoglobulin [immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin G (IgG)].Results The total effective rate of treatment in the observation group was 94.87%, higher than 76.92% in the control group, the difference was statistically significant(P<0.05); after treatment, the observation group RF, TNF-α, VEGF, IgA, IgM, IgG were lower than the control group, the difference was statistically significant(P<0.05).Conclusion Iguratimod combined with etanercept can effectively reduce the level of inflammatory factors, improve immunoglobulin and improve the therapeutic effect in patients with refractory rheumatoid arthritis.

参考文献/References:

[1]黄煜鹏,刘钢.托珠单抗治疗难治性类风湿关节炎的疗效与安全性[J].华西医学,2017,32(7):988-992.[2]王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:406-407.[3]杨利娜.艾拉莫德联合甲氨蝶呤治疗难治性类风湿关节炎效果观察[J].吉林医学,2017,38(2):341-342.[4]李学荣,陈永平,张榜硕,等.艾拉莫德联合依那西普对难治性类风湿关节炎患者CD4+、CD8+T细胞及免疫球蛋白的影响[J].免疫学杂志,2018,34(2):141-145.[5]谢李,邹庆华,石颖,等.艾拉莫德联合 ＭＴＸ对难治性类风湿关节炎患者IL-1、血清TNF-α、VEGF水平的影响[J].贵州医学,2018,42(7):831-832.

相似文献/References:

[1]张 伟.艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效[J].医学信息,2022,35(15):114.[doi:10.3969/j.issn.1006-1959.2022.15.026]
　ZHANG Wei.Efficacy of Iguratimod Combined with Celecoxib in the Treatment of Ankylosing Spondylitis[J].Medical Information,2022,35(09):114.[doi:10.3969/j.issn.1006-1959.2022.15.026]

更新日期/Last Update: 2020-05-01